1. Cell Cycle/DNA Damage
  2. CDK


CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

  • CDK1

  • CDK2

  • CDK3

  • CDK4

  • CDK5

  • CDK6

  • CDK7

  • CDK8

  • CDK9

  • CDK12

  • CDK13

  • CDK19

  • CDC

  • CLK

  • CDK16

  • CDK14

CDK 相关产品 (101):

Cat. No. Product Name Effect Purity
  • HY-50767
    Palbociclib Inhibitor 99.94%
    Palbociclib 是一种高特异性的 Cdk4Cdk6 抑制剂,IC50 分别为 11 nM 和 16 nM。
  • HY-16297
    LY2835219 Inhibitor 99.87%
    LY2835219 是具有选择性的 CDK4/6 抑制剂,能够抑制 CDK4/CDK6 的活性,IC50 分别为 2 nM 和 10 nM。
  • HY-50767A
    Palbociclib hydrochloride Inhibitor 99.94%
    Palbociclib hydrochloride 是一种高度特异性的 Cdk4Cdk6 抑制剂,IC50 值分别为 11 nM 和 16 nM。
  • HY-10492
    Dinaciclib Inhibitor 99.10%
    Dinaciclib 是一种有效的选择性 CDK 抑制剂,抑制 CDK2CDK5CDK1CDK9 活性,IC50 分别为 1,1,3 和 4 nM。
  • HY-15777
    LEE011 Inhibitor 99.82%
    LEE011 是一种高特异性的 CDK4/6 抑制剂,IC50 分别为 10 nM 和 39 nM。
  • HY-103712A
    CT7001 hydrochloride Inhibitor 99.98%
    CT7001 hydrochloride 是一种选择性的 CDK7 抑制剂,对 CDK7/CycH/MAT1 和 CDK2/cycE1 的 IC50 值分别为 41 nM 和 578 nM。
  • HY-112088
    AZD4573 Inhibitor 99.68%
    AZD4573 是 一个 CDK9 抑制剂, 其 IC50 值小于 3 nM,来自专利 US 20160376287 A1,实例 14。
  • HY-12871B
    BAY-1143572 Inhibitor 99.42%
    BAY-1143572 是一种口服有效的高选择性 PTEFb/CDK9 抑制剂。BAY-1143572 抑制 CDK9/CycT1IC50 为 13 nM。
  • HY-80013
    THZ1 Inhibitor 98.82%
    THZ1 是一种有效的选择性的共价 CDK7 抑制剂,IC50 为 3.2 nM。
  • HY-30237
    Roscovitine Inhibitor 99.77%
    Roscovitine 是一种有效的选择性 CDK 抑制剂,抑制 CDK5Cdc2CDK2IC50 分别为 0.2 μM,0.65 μM 和 0.7 μM。
  • HY-12529
    Ro-3306 Inhibitor
    Ro-3306 是一种有效的,选择性的 CDK1 抑制剂,对 CDK1,CDK1/cyclin B1 和 CDK2/cyclin E 的 Ki 值为分别为 20 nM,35 nM 和 340 nM。
  • HY-A0065
    Palbociclib isethionate Inhibitor 99.99%
    Palbociclib isethionate 是高度选择性的 CDK4/6 抑制剂,IC50 值分别为 11 nM/16 nM;对 CDK1/2/5,EGF,FGFR,PDGFR,InsR 等没有作用。
  • HY-80013A
    THZ1 Hydrochloride Inhibitor 98.70%
    THZ1 Hydrochloride 是一种有效的 CDK7 抑制剂,IC50 值为 3.2 nM。
  • HY-10005
    Flavopiridol Inhibitor 99.11%
    Flavopiridol 是一种 CDK 的广谱抑制剂,与 ATP 竞争性地抑制 CDK1,CDK2,CDK4 和 CDK6 的活性,IC50 值约为 40 nM。
  • HY-103618
    THZ531 Inhibitor 99.86%
    THZ531 是 CDK12CDK13 的共价抑制剂,其 IC50 值分别为 158 nM 和 69 nM。
  • HY-12871
    BAY-1143572 Racemate Inhibitor >98.0%
    BAY 1143572是高效选择性,具有口服活性的PTEFb/CDK9抑制剂;抑制AML细胞系的增殖的中间IC50为385 nM。
  • HY-12214A
    NVP-2 Inhibitor 99.29%
    NVP-2 是一种 CDK9 抑制剂,其 IC50 值为 0.5 nM。
  • HY-101212
    CYC065 Inhibitor 98.58%
    CYC065 是第二代口服有效的 ATP 竞争性的 CDK2 / CDK9 激酶抑制剂。
  • HY-10012
    AZD-5438 Inhibitor 99.84%
    AZD-5438 是一种有效的 CDK1/2/9 抑制剂,IC50 值分别为 16 nM/6 nM/20 nM;同时抑制 GSK3β,对 CDK5/6 的作用较弱。
  • HY-10580
    BIO Inhibitor 98.03%
    BIO 是一种有效的,选择性的,可逆的,ATP 竞争性的 GSK-3α/βCDK1-cyclinB 复合体抑制剂,能够抑制 (GSK-3α/β)/CDK1/CDK5 的活性,IC50 值分别为 5 nM/320 nM/83 nM。
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.